本研究的目的是评估超声/磁共振 (MR) 融合引导下经会阴激光消融 (TPLA) 作为难治性局灶性前列腺癌挽救治疗的技术可行性、安全性和有效性。共有 5 名患者接受过前列腺癌放射治疗 (RT) 和生化复发，经前列腺特异性抗原 (PSA) 水平和 MRI (3T mpMRI) 证实的患者被纳入本研究。使用1064nm二极管激光器进行局部消融。消融后随访为期18个月，包括定期PSA采样、3T mpMRI以及超声/MR融合引导下系统性、针对病灶治疗部位的活检。在门诊治疗方案中获得最佳的临床和生化结果。整个随访期间未检测到复发。TPLA局部治疗可有效控制RT难治性前列腺癌的局部复发，且无副作用或并发症。生活质量和功能结果得以保留，PSA 降低了 70% 以上。我们的研究调查了 TPLA 作为 RT 后低风险复发性前列腺癌的挽救治疗方法，证明了其耐受性、可行性和有效性。© 2023 作者。由英国放射学研究所出版。

The objective of this study was to assess the technical feasibility, safety, and efficacy of transperineal laser ablation (TPLA) guided by ultrasound/magnetic resonance (MR) fusion as a salvage treatment for refractory focal prostate cancer.A total of five patients who had undergone radiation therapy (RT) for prostate carcinoma and biochemical recurrence, confirmed by both prostate-specific antigen (PSA) levels and MRI (3T mpMRI), were enrolled in this study. Focal ablation was performed using a 1064 nm diode laser. Post-ablation follow-up was conducted for a duration of 18 months, which included regular PSA sampling, 3T mpMRI, and ultrasound/MR fusion-guided biopsies systematic and targeted at the site of the focal treatment.The focal ablation procedure was carried out in an outpatient setting regimen with optimal clinical and biochemical outcomes. No recurrence was detected throughout the follow-up period.TPLA focal treatment effectively manages local recurrences of RT refractory prostate cancer without side-effects or complications. Preservation of quality of life and functional outcomes, along with a >70% reduction in PSA, were achieved.Our study investigated TPLA as a salvage treatment for low-risk recurrent prostate cancer after RT, demonstrating its tolerability, feasibility, and effectiveness.© 2023 The Authors. Published by the British Institute of Radiology.